USP PDE-4 Inhibitor Powder Roflumilast (Daliresp) For Lungs Inflammatory Treatment
What is Roflumilast?
Roflumilast (trade names Daxas, Daliresp) is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease.
Roflumilast Basic Information
| Product Name |
Roflumilast |
| Alias |
B 9302-107, BY 217, BYK 20869, Daxas |
| CAS |
162401-32-3 |
| MF |
C17H14Cl2F2N2O3 |
| MW |
403.21 |
| EINECS |
223-583-8 |
| Purity |
99% |
| Grade |
Pharmaceutical Grade |
| Appearance |
white Crystalline Powder |
|
|
| Standard |
USP |
| Stock |
Mass Stock |
| Shelf Life |
2years |
Roflumilast Specification:
| Tests |
Specifications |
Results |
| Characters |
White to off-white crystalline powder |
Complies |
| Identification |
IR:similar to Reference Standard |
Complies |
| Appearance of solution |
Clear and colorless |
Complies |
| Loss on Drying |
≤0.5% |
0.06% |
| Sulphated Ash |
≤0.2% |
0.03% |
| Heavy metals |
≤0.002% |
Complies |
| Related Compouds |
Single Impurity ≤1.0%
Sum of Impurity≤2.0% |
Undetected
Undetected |
| Assay(Anhydrous) |
98.0% to 101.5% |
100.2% |
Roflumilast Usage
1) Roflumilast reduces inflammation in the lungs that leads to COPD (chronic obstructive pulmonary disease).
2) Roflumilast is used to prevent worsening of chronic obstructive pulmonary disease (COPD) in people with severe COPD and chronic bronchitis.
3) Roflumilast is not a bronchodilator. It will not treat a bronchospasm attack that has already begun.
Roflumilast side effects
Diarrhea, Weight loss, Nausea, Headache, Insomnia, Decreased appetite, Abdominal pain, Rhinitis, Sinusitis, Urinary tract infection, Depression, References
